MedTrace Logo

Peer-delivered Brief Motivational Interviewing Via Instant Messaging Interaction in Reducing the Drug Abuse Among Youth

NCT04672746 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2022-05-04

No results posted yet for this study

Summary

This is a two-arm, parallel-group, randomized controlled trial with an allocation ratio 1:1, by comparing the 12-month drug abuse reduction between the youth drug abusers who are individually randomized to participate in the intervention group receiving medical peer-delivered intervention of interactive brief motivational interviewing via instant messaging communication and those in the control group receiving general health information.

Conditions

  • Drug Abuse
  • Adolescent Behavior

Interventions

BEHAVIORAL

Brief MI interaction via instant communication

Telephone peer counselling+referral to treatment if required+The interaction communication using brief motivational interviewing via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.

BEHAVIORAL

General health information

Telephone peer counselling+referral to treatment if required+general health information via SMS, such as "do physical exercise for at least 30 min per week will keep you healthy" for 6 month with a frequency of least twice a week.

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Denise Shuk Ting Cheung, PhD · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-08-31
Completion
2023-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04672746 on ClinicalTrials.gov